NCT04623671View on ClinicalTrials.gov

Intravenous Infusion of CAP-1002 in Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

CAP-1002

Peripheral infusion of 150 million cardiosphere-derived cells (CDCs)

BIOLOGICAL

Placebo

Matching placebo solution

Trial Locations (4)

48202

Henry Ford Health System, Detroit

79109

PharmaTex Research, LLC, Amarillo

90048

Cedars-Sinai Medical Center, Los Angeles

95817

University of California Davis, Sacramento

All Listed Sponsors
lead

Capricor Inc.

INDUSTRY

NCT04623671 - Intravenous Infusion of CAP-1002 in Patients With COVID-19 | Biotech Hunter | Biotech Hunter